Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has taken a significant step forward in the development of its lead drug candidate ONC010 by engaging Nanosoft Polymers to conduct polymer process development and analytical characterization activities. The announcement, made via a press release, outlines a comprehensive effort to establish a scalable, reproducible, and analytically characterized polymer platform that will underpin future formulation, manufacturing, regulatory, and clinical development.
ONC010 is a nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor, a novel approach in oncology that targets DNA repair mechanisms in cancer cells. The partnership with Nanosoft, a company specializing in polymer science and nanoparticle drug delivery, is expected to strengthen the technical foundation of the ONC010 platform and facilitate future Good Manufacturing Practice (GMP) readiness. The activities include polymer synthesis optimization, development of characterization methodologies, molecular weight assessment, purification strategy refinement, and scalability assessments, all part of Onco-Innovations' chemistry, manufacturing, and controls (CMC) strategy.
The importance of this announcement lies in its implications for the progression of ONC010 toward clinical trials. By focusing on manufacturing scalability and reproducibility, Onco-Innovations is addressing a critical bottleneck in the translation of novel drug candidates from laboratory to clinic. A robust, well-characterized polymer platform is essential for consistent drug delivery and efficacy, as well as for meeting regulatory standards. The collaboration with Nanosoft, known for its expertise in polymer science, enhances the likelihood of successful scale-up and eventual commercialization.
Onco-Innovations, a Canadian-based company dedicated to cancer research and treatment, holds an exclusive worldwide license to patented technology targeting solid tumors. The company's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The current development activities with Nanosoft represent a concrete step toward realizing that mission.
For investors, the progress on ONC010's manufacturing development is a key milestone that could de-risk the program and increase its value. The collaboration also demonstrates Onco-Innovations' ability to leverage external expertise to advance its pipeline. The full press release can be accessed at https://nnw.fm/BeSoS. More information about Onco-Innovations is available at its newsroom at https://nnw.fm/ONNVF.
